S&P Futures
4,150.50 +8.75 (+0.21%) Dow Futures
32,854.00 +62.00 (+0.19%) Nasdaq Futures
13,209.75 +26.50 (+0.20%) Russell 2000 Futures
1,945.90 +4.80 (+0.25%) Crude Oil
90.84 +0.08 (+0.09%) Gold
1,804.60 -0.60 (-0.03%)
Synairgen plc (SNG.L)
Chart Events
Performance Outlook
| Previous Close | 26.60 |
| Open | 27.98 |
| Bid | 21.98 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 26.32 - 27.98 |
| 52 Week Range | 10.00 - 223.80 |
| Volume | |
| Avg. Volume | 1,247,431 |
| Market Cap | 55.369M |
| Beta (5Y Monthly) | -3.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -23.40 |
| Earnings Date | Sep 30, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 220.00 |
- Simply Wall St.
Can Synairgen (LON:SNG) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Business Wire
Synairgen Presents Detailed Analysis of Phase 3 SPRINTER Trial Evaluating SNG001 in Hospitalised COVID-19 Patients at ATS 2022
SOUTHAMPTON, England, May 16, 2022--Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the first presentation of the full data analysis from its Phase 3 SPRINTER trial evaluating the efficacy and safety of SNG001 in patients hospitalised with COVID-19.
- PR Newswire
Synairgen to present further analysis of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 International Conference
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that further analysis of its Phase 3 SPRINTER trial data will be presented at the ATS 2022 International Conference, being held between 13-18 May 2022 in San Francisco, at the following two sessions:
